공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 급성 관상동맥 증후군 치료 시장 : 종류별, 약제별, 치료별, 진단별, 최종사용자별 시장 조사, 예측(-2025년), COVID-19의 누적 영향

Acute Coronary Syndrome Therapeutic Market Research Report by Type, by Drug, by Treatment, by Diagnosis, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2021년 02월 상품 코드 982382
페이지 정보 영문 199 Pages
가격
US $ 3,949 ₩ 4,467,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 5,598,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 6,729,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 8,991,000 PDF (Site License) + Excel
US $ 9,949 ₩ 11,254,000 PDF (Enterprise License) + Excel


세계의 급성 관상동맥 증후군 치료 시장 : 종류별, 약제별, 치료별, 진단별, 최종사용자별 시장 조사, 예측(-2025년), COVID-19의 누적 영향 Acute Coronary Syndrome Therapeutic Market Research Report by Type, by Drug, by Treatment, by Diagnosis, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
발행일 : 2021년 02월 페이지 정보 : 영문 199 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

보고서는 5개 주요 통화(USD, EUR GBP, JPY, AUD)에 걸친 시장 규모와 예측을 제공합니다. 이것은 외화 환전 데이터를 바로 이용할 수 있는 경우에 조직 리더가 보다 나은 의사결정을 실시하는데 도움이 됩니다.

1. 급성 관상동맥 증후군 치료 시장 규모는 2020년 75억 8,226만 달러에서 2025년 말까지 102억 5,745만 달러로 성장할 것으로 예상됩니다.

2. 급성 관상동맥 증후군 치료 시장 규모는 2020년 66억 4,826만 유로에서 2025년 말까지 89억 9,393만 유로로 성장할 것으로 예상됩니다.

3. 급성 관상동맥 증후군 치료 시장 규모는 2020년 59억 1,032만 파운드에서 2025년 말까지 79억 9,562만 파운드로 성장할 것으로 예상됩니다.

4. 급성 관상동맥 증후군 치료 시장 규모는 2020년 8,092억 1,927만 엔에서 2025년 말까지 1조 947억 3,090만 엔으로 성장할 것으로 예상됩니다.

5. 급성 관상동맥 증후군 치료 시장 규모는 2020년 110억 1,044만 호주달러에서 2025년 말까지 148억 9,519만 호주달러로 성장할 것으로 예상됩니다.

시장 세분화와 커버리지:

이 조사 보고서는 세계의 급성 관상동맥 증후군 치료 시장을 분류하고, 매출을 예측하고, 다음 각 서브 마켓의 동향을 분석합니다.

종류에 기반한 부문에서 급성 관상동맥 증후군 치료 시장은 비ST상승형 심근경색, ST상승형 심근경색 및 바이알 불안정 협심증에 걸쳐 조사되었습니다.

약제에 기반한 부문에서 급성 관상동맥 증후군 치료 시장은 강압제, 항혈전제 및 스타틴에 걸쳐 조사되었습니다.

치료에 기반한 부문에서 급성 관상동맥 증후군 치료 시장은 약물 치료, 퇴원후 치료, 입원전 케어 및 재관류요법에 걸쳐 조사되었습니다. 약물 치료는 협심증 치료제, 항응고제 및 항혈소판제로 조사되었습니다.

진단에 기반한 부문에서 급성 관상동맥 증후군 치료 시장은 혈액검사, 컴퓨터 단층촬영 혈관조영, 관상동맥 조영, 심초음파검사 및 이미징에 걸쳐 조사되었습니다.

최종사용자에 기반한 부문에서 급성 관상동맥 증후군 치료 시장은 학술기관, 진단 센터 및 병원과 진료소로 조사되었습니다.

"아시아태평양은 예측기간 중 최고의 성장을 나타낼 것으로 예측됩니다"

지역별로 시장은 아메리카, 아시아태평양 및 유럽·중동·아프리카로 분류되어 조사되었습니다. 아메리카는 아르헨티나, 브라질, 캐나다, 멕시코 및 미국으로, 아시아태평양은 호주, 중국, 인도, 인도네시아, 일본, 말레이시아, 필리핀, 한국, 태국으로, 유럽과 중동 및 아프리카는 프랑스, 독일, 이탈리아, 네덜란드, 카타르, 러시아, 사우디아라비아, 남아프리카공화국, 스페인, 아랍에미리트 및 영국으로 조사되었습니다. 아메리카는 2020년에 급성 관상동맥 증후군 치료 시장에서 최대 규모를 나타냈습니다. 한편 아시아태평양은 예측기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.

기업 개요:

보고서는 AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., XOMA Corporation 등 세계 급성 관상동맥 증후군 치료 시장의 주요 벤더에 의한 최근의 중요한 진전과 혁신 프로파일을 깊이 탐구하고 있습니다.

COVID-19의 누적 영향:

COVID-19는 거의 모든 업계에 영향을 미친 전례 없는 세계적인 공중위생상 긴급사태이기 때문에 예측기간 중 업계의 성장에 장기적인 영향을 미칠 것으로 예측됩니다. 우리가 진행중인 조사는 조사 프레임워크를 증폭하고, 기초가 되는 COVID-19의 문제와 향후 잠재적 방향을 확실히 포함시키고 있습니다. 조사는 소비자의 행동과 수요 변화, 구입 패턴, 공급망 재라우팅, 현재 시장 힘의 역학 및 정부의 중요한 개입을 고려한 COVID-19에 관한 인사이트를 제공합니다. 갱신된 조사는 시장에 대한 COVID-19의 영향을 고려하고, 인사이트, 분석, 추정 및 예측을 제공합니다.

360iResearch™ FPNV Positioning Matrix:

360iResearch™ FPNV Positioning Matrix는 기업이 보다 나은 의사결정을 실시하고, 경쟁 상황을 이해하는데 도움이 되는 비지니스 전략(비지니스의 성장, 업계의 커버리지, 경제적 실행 가능성, 채널 지원)과 제품 만족도(가성비, 사용 용이성, 제품 기능 및 고객 지원)에 기반해 시장 벤더를 평가 및 분류합니다.

360iResearch™ Competitive Strategic Window(경쟁력 있는 전략적 창):

360iResearch™ Competitive Strategic Window는 시장, 용도 및 지역의 관점에서 경쟁 상황을 분석합니다. 이것은 벤더가 향후 성장 전망에 대한 능력과 기회 사이의 조정 또는 적합을 정의하는데 도움이 됩니다. 예측기간 중 벤더가 지속적인 합병 및 인수 전략, 지역의 확대, 연구개발 및 신제품 도입 전략을 채용하고, 새로운 사업 확대와 성장을 실행하기 위한 최적 또는 유리한 적합을 정의합니다.

보고서는 다음 지침에 관한 인사이트를 제공합니다.

1. 시장 침투 : 주요 기업에 의해 제공되는 시장에 관한 종합적인 정보

2. 시장 개발 : 수익성 높은 신흥 시장에 관한 상세한 정보와 시장 분석

3. 시장 다양화 : 신제품 발매, 미개발 지역, 최근의 개발 및 투자에 관한 상세 정보

4. 경쟁력 있는 평가와 인텔리전스 : 주요 기업의 시장 점유율, 전략, 제품, 제조능력의 철저한 평가

5. 제품 개발과 혁신 : 향후 테크놀러지, R&D 활동 및 신제품 개발에 관한 인텔리전트 인사이트

보고서는 다음과 같은 질문에 답합니다.

1. 세계 시장 규모와 예측은 어떠한가?

2. 예측기간 중 시장을 형성하는 COVID-19의 저해요인과 영향은 무엇인가?

3. 예측기간 중 투자하는 제품, 부문, 용도, 분야는 무엇인가?

4. 시장의 기회 Competitive Strategic Window는 무엇인가?

5. 시장의 기술 동향과 규제 체계는 무엇인가?

6. 시장에 참여하기에 적합하다고 생각되는 모드와 전략적 움직임은 무엇인가?

세계의 급성 관상동맥 증후군 치료(Acute Coronary Syndrome Therapeutic) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 종류·약제·치료·진단·최종사용자·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요 등 체계적인 정보를 제공합니다.

목차

제1장 서문

  • 조사 목적
  • 시장 세분화와 커버리지
  • 조사 대상 기간
  • 통화와 가격
  • 언어
  • 제한
  • 이해관계자

제2장 조사 방법

  • 조사 과정
    • 정의 : 조사 목적
    • 결정 : 조사 디자인
    • 준비 : 조사 기기
    • 수집 : 데이터 소스
    • 분석 : 데이터 해석
    • 책정 : 데이터 검증
    • 공개 : 조사 보고서
    • 반복 : 보고서 갱신
  • 조사 실행
    • 개시 : 조사 과정
    • 계획 : 조사 계획 작성
    • 실행 : 조사 실시
    • 검증 : 발견과 분석
    • 출판물 : 조사 보고
  • 조사 성과

제3장 주요 요약

  • 서론
  • 시장 전망
  • 의약품 전망
  • 종류 전망
  • 치료 전망
  • 진단 전망
  • 최종사용자 전망
  • 지역 전망
  • 경쟁사 전망

제4장 시장 개요

  • 서론
  • COVID-19의 누적 영향
  • 지역적 성장 기회

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • Porters Five Forces 분석
    • 신규 참여업체의 위협
    • 대체품의 위협
    • 고객의 협상력
    • 공급 기업의 협상력
    • 업계의 경쟁

제6장 종류별

  • 서론
  • 비ST상승형 심근경색
  • ST상승형 심근경색
  • 바이알 불안정 협심증

제7장 약제별

  • 서론
  • 강압제
  • 항혈전제
  • 스타틴

제8장 치료별

  • 서론
  • 약물 치료
    • 항협심증제
    • 항응고제
    • 항혈소판제
  • 퇴원후 치료
  • 입원전 케어
  • 재관류요법

제9장 진단별

  • 서론
  • 혈액검사
  • 컴퓨터 단층촬영 혈관조영
  • 관상동맥 조영
  • 심초음파검사
  • 이미징

제10장 최종사용자별

  • 서론
  • 학술기관
  • 진단 센터
  • 병원과 클리닉

제11장 아메리카

  • 서론
  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제12장 아시아태평양

  • 서론
  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 한국
  • 태국

제13장 유럽, 중동 및 아프리카

  • 서론
  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트
  • 영국

제14장 경쟁 상황

  • FPNV 포지셔닝 매트릭스
    • 상한
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 시장 점유율 분석
  • 경쟁 시나리오
    • 합병과 인수
    • 합의, 협업 및 파트너십
    • 신제품 발매와 강화
    • 투자와 자금 조달
    • 상, 표창, 확대

제15장 기업 개요

  • AbbVie Inc.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Gilead Sciences, Inc.,
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

제16장 부록

  • 논의 가이드
KSM 21.02.02

List of Figures

  • FIGURE 1. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 12. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 14. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: MARKET DYNAMICS
  • FIGURE 15. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 16. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
  • FIGURE 17. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2025
  • FIGURE 19. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION, 2020 VS 2025 (USD MILLION)
  • FIGURE 21. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY VIAL UNSTABLE ANGINA, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 VS 2025 (%)
  • FIGURE 23. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2025
  • FIGURE 25. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIHYPERTENSIVE, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTITHROMBOTIC, 2020 VS 2025 (USD MILLION)
  • FIGURE 27. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY STATINS, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 VS 2025 (%)
  • FIGURE 29. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 VS 2025 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2025
  • FIGURE 31. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG TREATMENT, 2020 VS 2025 (USD MILLION)
  • FIGURE 32. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIANGINAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 33. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTICOAGULANT, 2020 VS 2025 (USD MILLION)
  • FIGURE 34. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIPLATELET DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 35. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY POST DISCHARGE TREATMENT, 2020 VS 2025 (USD MILLION)
  • FIGURE 36. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY PREHOSPITAL CARE, 2020 VS 2025 (USD MILLION)
  • FIGURE 37. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REPERFUSION THERAPY, 2020 VS 2025 (USD MILLION)
  • FIGURE 38. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 VS 2025 (%)
  • FIGURE 39. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2025
  • FIGURE 41. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY BLOOD TESTS, 2020 VS 2025 (USD MILLION)
  • FIGURE 42. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY COMPUTERIZED TOMOGRAPHY ANGIOGRAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 43. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY CORONARY ANGIOGRAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 44. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ECHOCARDIOGRAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 45. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY IMAGING, 2020 VS 2025 (USD MILLION)
  • FIGURE 46. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 VS 2025 (%)
  • FIGURE 47. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 VS 2025 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2025
  • FIGURE 49. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ACADEMIC INSTITUTES, 2020 VS 2025 (USD MILLION)
  • FIGURE 50. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, 2020 VS 2025 (USD MILLION)
  • FIGURE 51. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY HOSPITAL & CLINICS, 2020 VS 2025 (USD MILLION)
  • FIGURE 52. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 53. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 55. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 61. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 62. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 63. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 64. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 65. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 66. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 67. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 68. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 69. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 70. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 71. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 72. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 73. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 74. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 75. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 76. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 77. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 78. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 79. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 80. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 81. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 82. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 83. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 84. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 85. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 86. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
  • FIGURE 87. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
  • FIGURE 88. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 89. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET, BY TYPE

List of Tables

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY VIAL UNSTABLE ANGINA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIHYPERTENSIVE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTITHROMBOTIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY STATINS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG TREATMENT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIANGINAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTICOAGULANT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIPLATELET DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY POST DISCHARGE TREATMENT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY PREHOSPITAL CARE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REPERFUSION THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY COMPUTERIZED TOMOGRAPHY ANGIOGRAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY CORONARY ANGIOGRAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ECHOCARDIOGRAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY IMAGING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY HOSPITAL & CLINICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 126. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 127. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 128. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 129. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 130. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 131. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 132. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 133. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 134. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 135. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 136. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 137. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 138. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 139. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 140. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 141. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 142. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 143. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 144. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 145. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 146. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 147. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 148. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 149. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 150. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 151. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 152. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 153. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 154. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 155. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 156. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 157. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 158. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 159. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 160. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 161. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 162. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 163. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 164. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 165. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 166. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 167. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 168. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 169. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 170. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 171. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 172. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 173. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: SCORES
  • TABLE 174. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: BUSINESS STRATEGY
  • TABLE 175. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: PRODUCT SATISFACTION
  • TABLE 176. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: RANKING
  • TABLE 177. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: MERGER & ACQUISITION
  • TABLE 178. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 179. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 180. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: INVESTMENT & FUNDING
  • TABLE 181. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 182. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: LICENSE & PRICING

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Acute Coronary Syndrome Therapeutic Market is expected to grow from USD 7,582.26 Million in 2020 to USD 10,257.45 Million by the end of 2025.

2. The Global Acute Coronary Syndrome Therapeutic Market is expected to grow from EUR 6,648.26 Million in 2020 to EUR 8,993.93 Million by the end of 2025.

3. The Global Acute Coronary Syndrome Therapeutic Market is expected to grow from GBP 5,910.32 Million in 2020 to GBP 7,995.62 Million by the end of 2025.

4. The Global Acute Coronary Syndrome Therapeutic Market is expected to grow from JPY 809,219.27 Million in 2020 to JPY 1,094,730.90 Million by the end of 2025.

5. The Global Acute Coronary Syndrome Therapeutic Market is expected to grow from AUD 11,010.44 Million in 2020 to AUD 14,895.19 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Acute Coronary Syndrome Therapeutic to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Acute Coronary Syndrome Therapeutic Market studied across Non-ST-elevation Myocardial Infarction, ST-elevation Myocardial Infarction, and Vial Unstable Angina.

Based on Drug, the Acute Coronary Syndrome Therapeutic Market studied across Antihypertensive, Antithrombotic, and Statins.

Based on Treatment, the Acute Coronary Syndrome Therapeutic Market studied across Drug Treatment, Post Discharge Treatment, Prehospital Care, and Reperfusion Therapy. The Drug Treatment further studied across Antianginal Drug, Anticoagulant, and Antiplatelet Drug.

Based on Diagnosis, the Acute Coronary Syndrome Therapeutic Market studied across Blood Tests, Computerized Tomography Angiogram, Coronary Angiogram, Echocardiogram, and Imaging.

Based on End User, the Acute Coronary Syndrome Therapeutic Market studied across Academic Institutes, Diagnostic Centers, and Hospital & Clinics.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the Acute Coronary Syndrome Therapeutic Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Acute Coronary Syndrome Therapeutic Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Acute Coronary Syndrome Therapeutic Market including AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Gilead Sciences, Inc.,, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Acute Coronary Syndrome Therapeutic Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Acute Coronary Syndrome Therapeutic Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Coronary Syndrome Therapeutic Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Coronary Syndrome Therapeutic Market?

4. What is the competitive strategic window for opportunities in the Global Acute Coronary Syndrome Therapeutic Market?

5. What are the technology trends and regulatory frameworks in the Global Acute Coronary Syndrome Therapeutic Market?

6. What are the modes and strategic moves considered suitable for entering the Global Acute Coronary Syndrome Therapeutic Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Type Outlook
  • 3.5. Treatment Outlook
  • 3.6. Diagnosis Outlook
  • 3.7. End User Outlook
  • 3.8. Geography Outlook
  • 3.9. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased cases of atherosclerosis (myocardial infarction) and unstable angina
      • 5.1.1.2. Growing aging population and poor immune systems
      • 5.1.1.3. Increased pharmaceutical R&D investment and introduction of innovative drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Obstruction due to less number of approved drugs for the treatment of acute coronary syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Reperfusion of the myocardium and prevent reinfarction in order to promote patient survival
      • 5.1.3.2. Extensive pipeline drugs with properties, such as high patient compliance and improved safety
      • 5.1.3.3. Improving health care infrastructure and government reimbursement programs
    • 5.1.4. Challenges
      • 5.1.4.1. Cost and formulation
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Acute Coronary Syndrome Therapeutic Market, By Type

  • 6.1. Introduction
  • 6.2. Non-ST-elevation Myocardial Infarction
  • 6.3. ST-elevation Myocardial Infarction
  • 6.4. Vial Unstable Angina

7. Global Acute Coronary Syndrome Therapeutic Market, By Drug

  • 7.1. Introduction
  • 7.2. Antihypertensive
  • 7.3. Antithrombotic
  • 7.4. Statins

8. Global Acute Coronary Syndrome Therapeutic Market, By Treatment

  • 8.1. Introduction
  • 8.2. Drug Treatment
    • 8.2.1. Antianginal Drug
    • 8.2.2. Anticoagulant
    • 8.2.3. Antiplatelet Drug
  • 8.3. Post Discharge Treatment
  • 8.4. Prehospital Care
  • 8.5. Reperfusion Therapy

9. Global Acute Coronary Syndrome Therapeutic Market, By Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Tests
  • 9.3. Computerized Tomography Angiogram
  • 9.4. Coronary Angiogram
  • 9.5. Echocardiogram
  • 9.6. Imaging

10. Global Acute Coronary Syndrome Therapeutic Market, By End User

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Diagnostic Centers
  • 10.4. Hospital & Clinics

11. Americas Acute Coronary Syndrome Therapeutic Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Acute Coronary Syndrome Therapeutic Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. South Korea
  • 12.10. Thailand

13. Europe, Middle East & Africa Acute Coronary Syndrome Therapeutic Market

  • 13.1. Introduction
  • 13.2. France
  • 13.3. Germany
  • 13.4. Italy
  • 13.5. Netherlands
  • 13.6. Qatar
  • 13.7. Russia
  • 13.8. Saudi Arabia
  • 13.9. South Africa
  • 13.10. Spain
  • 13.11. United Arab Emirates
  • 13.12. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
    • 14.1.1. Quadrants
    • 14.1.2. Business Strategy
    • 14.1.3. Product Satisfaction
  • 14.2. Market Ranking Analysis
  • 14.3. Market Share Analysis
  • 14.4. Competitor SWOT Analysis
  • 14.5. Competitive Scenario
    • 14.5.1. Merger & Acquisition
    • 14.5.2. Agreement, Collaboration, & Partnership
    • 14.5.3. New Product Launch & Enhancement
    • 14.5.4. Investment & Funding
    • 14.5.5. Award, Recognition, & Expansion

15. Company Usability Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Amgen Inc.
  • 15.3. Arena Pharmaceuticals, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Baxter International Inc.
  • 15.6. Bayer AG
  • 15.7. Biogen Inc.
  • 15.8. Boehringer Ingelheim International GmbH
  • 15.9. Eli Lilly and Company
  • 15.10. Gilead Sciences, Inc.
  • 15.11. Gilead Sciences, Inc.,
  • 15.12. GlaxoSmithKline PLC
  • 15.13. Johnson & Johnson Services, Inc.
  • 15.14. Merck & Co., Inc.
  • 15.15. Novartis International AG
  • 15.16. Pfizer Inc.
  • 15.17. Teva Pharmaceutical Industries Ltd.
  • 15.18. XOMA Corporation

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing
Back to Top
전화 문의
F A Q